Reasons for treating secondary AML as de novo AML

Lene Sofie Granfeldt Ostgård; Eigil Kjeldsen; Mette Skov Holm; Peter De Nully Brown; Bjarne Bach Pedersen; Knud Bendix; Preben Johansen; Jørgen Schøler Kristensen; Jan Maxwell Nørgaard

doi:10.1111/j.1600-0609.2010.01464.x

Reasons for treating secondary AML as de novo AML

Lene Sofie Granfeldt Ostgård, Eigil Kjeldsen, Mette Skov Holm, Peter De Nully Brown, Bjarne Bach Pedersen, Knud Bendix, Preben Johansen, Jørgen Schøler Kristensen, Jan Maxwell Nørgaard

Institut for Klinisk Medicin

37 Citationer (Scopus)

Abstract

In a Danish bi-regional registry-based study, we conducted an analysis of the incidence and clinical importance of secondary acute myeloid leukaemia (AML). In a total of 630 cases of AML, we found 157 (25%) cases of secondary AML. The secondary leukaemia arose from MDS (myelodysplastic syndrome) in 77 cases (49%), CMPD (chronic myeloproliferative disorder) in 43 cases (27%) and was therapy-related AML (t-AML) in 37 cases (24%). Median age at diagnosis of AML was 69 yr in secondary cases when compared to 66 yr in de novo cases (P = 0.006). In univariate analyses, secondary AML was associated with an inferior complete remission (CR) rate (P = 0.008) and poorer overall survival (OS, P = 0.003) whereas in complete remitters, disease-free survival (DFS) of secondary cases was equal to that of de novo cases. Interestingly, in all further analyses of CR-rates, OS and DFS, when correcting for the influence of age, cytogenetic abnormalities, performance status and leucocyte count (WBC), presence of secondary AML completely lost prognostic significance. We conclude that the presence of secondary AML does not per se convey an unfavourable prognosis and that patients with secondary AML should be offered the chance of benefiting from treatment according to current frontline AML protocols.

Originalsprog	Engelsk
Tidsskrift	European Journal of Haematology
Vol/bind	85
Udgave nummer	3
Sider (fra-til)	217-26
Antal sider	10
ISSN	0902-4441
DOI	https://doi.org/10.1111/j.1600-0609.2010.01464.x
Status	Udgivet - 1 sep. 2010

Adgang til dokumentet

10.1111/j.1600-0609.2010.01464.x

Citationsformater

@article{a3a3e67a365947abadebaa9a0c1041a9,

title = "Reasons for treating secondary AML as de novo AML",

abstract = "In a Danish bi-regional registry-based study, we conducted an analysis of the incidence and clinical importance of secondary acute myeloid leukaemia (AML). In a total of 630 cases of AML, we found 157 (25%) cases of secondary AML. The secondary leukaemia arose from MDS (myelodysplastic syndrome) in 77 cases (49%), CMPD (chronic myeloproliferative disorder) in 43 cases (27%) and was therapy-related AML (t-AML) in 37 cases (24%). Median age at diagnosis of AML was 69 yr in secondary cases when compared to 66 yr in de novo cases (P = 0.006). In univariate analyses, secondary AML was associated with an inferior complete remission (CR) rate (P = 0.008) and poorer overall survival (OS, P = 0.003) whereas in complete remitters, disease-free survival (DFS) of secondary cases was equal to that of de novo cases. Interestingly, in all further analyses of CR-rates, OS and DFS, when correcting for the influence of age, cytogenetic abnormalities, performance status and leucocyte count (WBC), presence of secondary AML completely lost prognostic significance. We conclude that the presence of secondary AML does not per se convey an unfavourable prognosis and that patients with secondary AML should be offered the chance of benefiting from treatment according to current frontline AML protocols.",

author = "Ostg{\aa}rd, {Lene Sofie Granfeldt} and Eigil Kjeldsen and Holm, {Mette Skov} and Brown, {Peter De Nully} and Pedersen, {Bjarne Bach} and Knud Bendix and Preben Johansen and Kristensen, {J{\o}rgen Sch{\o}ler} and N{\o}rgaard, {Jan Maxwell}",

year = "2010",

month = sep,

day = "1",

doi = "10.1111/j.1600-0609.2010.01464.x",

language = "English",

volume = "85",

pages = "217--26",

journal = "European Journal of Haematology",

issn = "0902-4441",

publisher = "Wiley-Blackwell",

number = "3",

}

TY - JOUR

T1 - Reasons for treating secondary AML as de novo AML

AU - Ostgård, Lene Sofie Granfeldt

AU - Kjeldsen, Eigil

AU - Holm, Mette Skov

AU - Brown, Peter De Nully

AU - Pedersen, Bjarne Bach

AU - Bendix, Knud

AU - Johansen, Preben

AU - Kristensen, Jørgen Schøler

AU - Nørgaard, Jan Maxwell

PY - 2010/9/1

Y1 - 2010/9/1

N2 - In a Danish bi-regional registry-based study, we conducted an analysis of the incidence and clinical importance of secondary acute myeloid leukaemia (AML). In a total of 630 cases of AML, we found 157 (25%) cases of secondary AML. The secondary leukaemia arose from MDS (myelodysplastic syndrome) in 77 cases (49%), CMPD (chronic myeloproliferative disorder) in 43 cases (27%) and was therapy-related AML (t-AML) in 37 cases (24%). Median age at diagnosis of AML was 69 yr in secondary cases when compared to 66 yr in de novo cases (P = 0.006). In univariate analyses, secondary AML was associated with an inferior complete remission (CR) rate (P = 0.008) and poorer overall survival (OS, P = 0.003) whereas in complete remitters, disease-free survival (DFS) of secondary cases was equal to that of de novo cases. Interestingly, in all further analyses of CR-rates, OS and DFS, when correcting for the influence of age, cytogenetic abnormalities, performance status and leucocyte count (WBC), presence of secondary AML completely lost prognostic significance. We conclude that the presence of secondary AML does not per se convey an unfavourable prognosis and that patients with secondary AML should be offered the chance of benefiting from treatment according to current frontline AML protocols.

AB - In a Danish bi-regional registry-based study, we conducted an analysis of the incidence and clinical importance of secondary acute myeloid leukaemia (AML). In a total of 630 cases of AML, we found 157 (25%) cases of secondary AML. The secondary leukaemia arose from MDS (myelodysplastic syndrome) in 77 cases (49%), CMPD (chronic myeloproliferative disorder) in 43 cases (27%) and was therapy-related AML (t-AML) in 37 cases (24%). Median age at diagnosis of AML was 69 yr in secondary cases when compared to 66 yr in de novo cases (P = 0.006). In univariate analyses, secondary AML was associated with an inferior complete remission (CR) rate (P = 0.008) and poorer overall survival (OS, P = 0.003) whereas in complete remitters, disease-free survival (DFS) of secondary cases was equal to that of de novo cases. Interestingly, in all further analyses of CR-rates, OS and DFS, when correcting for the influence of age, cytogenetic abnormalities, performance status and leucocyte count (WBC), presence of secondary AML completely lost prognostic significance. We conclude that the presence of secondary AML does not per se convey an unfavourable prognosis and that patients with secondary AML should be offered the chance of benefiting from treatment according to current frontline AML protocols.

U2 - 10.1111/j.1600-0609.2010.01464.x

DO - 10.1111/j.1600-0609.2010.01464.x

M3 - Journal article

SN - 0902-4441

VL - 85

SP - 217

EP - 226

JO - European Journal of Haematology

JF - European Journal of Haematology

IS - 3

ER -

Reasons for treating secondary AML as de novo AML

Abstract

Adgang til dokumentet

Fingeraftryk

Citationsformater